RYBREVANT 350MG INJECTION

About RYBREVANT 350MG INJECTION

Rybrevant 350MG Injection contains amivantamab 350mg. It attaches to both EGFR and MET on cancer cells, blocking their growth signals and flagging them to the immune system, which is why it is classed as an EGFR-MET bispecific antibody (targeted therapy). Specialists use it for non-small cell lung cancer with EGFR exon 20 insertion or other EGFR mutations. During treatment expect regular checks such as infusion reactions, skin and nail changes, and lung symptoms. Made by Johnson & Johnson; pack size 1 vial. MRP Rs 85,075.89 as per the NPPA revision of 9 November 2026. Never start, stop or change it on your own - the oncologist or specialist decides the plan.